Stroke Devices: Hope Amid Headwinds

Article preview from IN VIVO - October 22, 2013

Despite market headwinds, the endovascular treatment of acute ischemic stroke remains a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although advances in neurothrombectomy devices, access catheters, imaging, and neuroprotective therapies have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.

Stroke Devices: Hope Amid Headwinds

Article preview from IN VIVO - October 22, 2013

The endovascular treatment of acute ischemic stroke is a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although technological advances have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.

Despite market headwinds, endovascular treatments for acute ischemic stroke (AIS) continue to represent a large, rapidly emerging market with a worldwide opportunity estimated at more than $1 billion. Several factors have been slowing growth in this market of late, including recent clinical trial results, looming threats to reimbursement, increasing regulatory requirements, and a challenging funding environment. However, the long-term outlook remains positive. The fundamentals are sound and will continue to drive growth in this space for many years to come.

The demand is clearly there. According to the American Heart Association (AHA)/American Stroke Association (ASA), almost 800,000 people in the US experience a new or recurrent stroke each year. Stroke is the number-four cause of death in the US and the number-one cause of disability. Because the population is aging and the risk of stroke more than doubles for each successive decade after the aget of 55, by 2030, nearly 4% of the US adult population is projected to have had a stroke. That translates to a projected increase in stroke prevalence of 3.4 million individuals between 2012 and 2030. Of course, these projections mean the annual costs associated with stroke also will increase substantially over the next two decades. Between 2012 and 2030, the total direct medical-related costs of stroke are projected to more than double, from almost $72 billion to $184 billion annually. When indirect annual costs related to the loss of productivity are included, the total annual cost of stroke in the US is projected to grow to almost $240 billion by 2030 – an increase of 129%.

Continued...

Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512